Year in review: CELLINK’s biggest news of 2019

As another year comes to a close, we want to thank everyone in the bioprinting community for another tremendous year of innovation, collaboration and excellence! To celebrate, we’ve put together a quick summary of the biggest highlights from 2019.

 

1. We joined a collaboration to improve treatment for burn patients. Along with Umeå University and GE Healthcare, CELLINK joined efforts to help develop transplantable skin constructs that can give burn patients a better quality of life. The research will be conducted through collaborations with burn centers in Norway, Finland, Denmark and the Netherlands, and the researchers are slated to begin treating patients in 2020.

 

2. We acquired single-cell dispensing company cytena GmbH. CELLINK acquired cytena to expand our product offering and provide a more complete solution for 3D cell culturing. The cytena team developed a patented single-cell printer technology, which enables users to isolate and dispense single cells in a documented, gentle and sterile process. The single-cell printers have been manufactured in Germany since 2015 and are marketed worldwide. Most of the top-ten pharmaceutical companies use cytena’s single-cell printers to produce clonal cell lines.

 

 

 

3. Our Holograph X was honored with the Merch Innovation Award. The Holograph X won the Merck Innovation Award, a top honor for innovative medical devices with potential to change what’s possible in pharmaceutical medicine. In the award announcement, Merck senior investigator Tim Rhodes recognized CELLINK and California-based development partner Prellis Biologics for their “cutting-edge technology.” The award was announced at Merck Tech Symposium 2019, a forum focused on new technologies that provide decision-making insight in medicine.

 

4. Research was published validating I-DOT’s potential to support cancer research. The Karolinska Institute published exciting research that demonstrated I-DOT’s capability to empower genetic research in cancer diagnostics. The Karolinska Institute operates at the forefront of cancer research. Their study, published in the scientific journal Nature Communications, showed that I-DOT facilitates methods that enable reduced costs, faster results and enhanced reproducibility.

 

5. We opened a new office in Lyon, France. Qu’est-ce c’est? To strengthen our presence in Europe, CELLINK opened its doors to the flourishing biotech scene in France. This office offers our full product portfolio and aims to enable a closer dialogue with the local bioprinting community present there.

 

6. We brought bioprinting to space (and back!) In June 2019, CELLINK collaborated with Uppsala University to study the influences of microgravity and hypergravity on living systems. Our BIO X bioprinter and bioinks were used to bioprint cells that were launched to space on a MASER 14 rocket by the Swedish Space Corporation on June 24, 2019.And in December 2019, we announced our partnership with Made In Space to identify technology development opportunities on platforms like the International Space Station. Made In Space is the industry leader for space manufacturing technologies.

Bioprinting has the potential to mitigate crew health and safety risks on long-duration spaceflight missions where access to standard medical facilities isn’t readily available. Bioprinting capabilities optimized to work in the space environment could enable future crews to develop skin and bone patches to aid in would healing in space.

 

7. Our BIO X won a prestigious GOOD DESIGN Award from the The Chicago Athenaeum Museum. The BIO X bioprinter won a GOOD DESIGN Award in the medical category for its product excellence and endurance as well as its strong public identity. For over seven decades since its inception, the Chicago Athenaeum has honored both products and industry leaders in design and manufacturing that have chartered new direction and pushed the envelope for competitive products in the world marketplace. Submissions to the program are judged by a jury of distinguished design professionals and leading industry specialists on the highest aesthetic in terms of innovative design, new technologies, form, materials, construction, concept, function, utility, energy efficiency and sensitivity to the environment.

 

8. BIO X was granted design patents from both the United States and Sweden. The U.S. Patent and Trademark Office demonstrates the uniqueness and innovation of the BIO X, our standalone bioprinter designed to maximize user-friendliness and functionality. The patent protects the BIO X’s one-of-a-kind design and distinguishes CELLINK from its competitors in the bioprinting field.The patent protection from the Sweden Patent and Registration Office also verifies a product’s uniqueness and height of innovation. These patents act as proof of our commitment to developing cutting-edge technologies and help us build long-term business with the right focus and value for our customers and shareholders.

9. BIO X won the Grand Award of Design. The Swedish Teknikföretagen’s Grand Award of Design highlights design as a key to competitiveness and profitability. In the yearly competition, a jury of prominent experts in design choose a winner.According to the jury, CELLINK succeeded not only in building a revolutionary bioprinter, but also in enabling its accessibility to researchers through extensive cost-effective collaborations. Through a smart futuristic design that has a low financial threshold in use, BIO X has the ideal design for solving complex problems.

 

And there is more to come in 2020! CELLINK continues to invest significantly in resources, technology and a talented team to support you and your work. This year, we’re continuing our strategies designed to offer the best and most innovative tools possible to help strengthen bioprinting research worldwide.

More from Our Blog